|
|
| | H-Arg-Gln-OH hydrochloride salt Basic information |
| Product Name: | H-Arg-Gln-OH hydrochloride salt | | Synonyms: | H-ARG-GLN-OH HCL;H-Arg-Gln-OH;L-Glutamine, L-arginyl-;(S)-5-Amino-2-((S)-2-amino-5-guanidinopentanamido)-5-oxopentanoic acid;Arg-Gln;Arginyl-Glutamine;H-Arg-Gln-OH hydrochloride salt | | CAS: | 2483-17-2 | | MF: | C11H22N6O4 | | MW: | 302.33 | | EINECS: | | | Product Categories: | | | Mol File: | 2483-17-2.mol |  |
| | H-Arg-Gln-OH hydrochloride salt Chemical Properties |
| storage temp. | -15°C | | Sequence | Arg-Gln |
| | H-Arg-Gln-OH hydrochloride salt Usage And Synthesis |
| Uses | Arginyl-Glutamine is a dipeptide that can decrease VEGF levels and inhibit retinal neovascularization in a mouse model of oxygen-induced retinopathy[1]. | | Definition | ChEBI: Arg-Gln is a dipeptide formed from L-arginyl and L-glutamine residues. It has a role as a metabolite. | | in vivo | Arginyl-Glutamine (1-5 g/kg/day as a hydrochloride salt; i.p.; twice daily) dramatically inhibits retinal neovascularization in the mouse oxygen-induced retinopathy (OIR) model[1]. | Animal Model: | C57BL6/J mouse pups, oxygen-induced retinopathy (OIR) model[1] | | Dosage: | 1.0, 2.5, or 5 g/kg per day | | Administration: | Intraperitoneal injection, twice daily | | Result: | Significantly decreased preretinal nuclei. Reduced neovascular tufts and vascular leakage in retinal vessels. Reduced preretinal neovascularization by 82% ± 7% and reduced VEGF mRNA by 64% ± 9% at 5 g/kg per day.
|
| | References | [1] Neu J, et al. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2006 Jul;47(7):3151-5. DOI:10.1167/iovs.05-1473 |
| | H-Arg-Gln-OH hydrochloride salt Preparation Products And Raw materials |
|